Aethlon Medical (NASDAQ:AEMD) Stock Price Passes Below Two Hundred Day Moving Average – Time to Sell?

Aethlon Medical, Inc. (NASDAQ:AEMD)’s stock price passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $2.15 and traded as low as $0.6830. Aethlon Medical shares last traded at $0.6940, with a volume of 214,260 shares traded.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Aethlon Medical in a research note on Monday, April 20th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Reduce”.

Aethlon Medical Trading Up 1.9%

The firm has a 50 day moving average of $1.78 and a two-hundred day moving average of $2.12. The stock has a market capitalization of $1.68 million, a PE ratio of -0.05 and a beta of 1.41.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Aethlon Medical stock. Citadel Advisors LLC acquired a new position in Aethlon Medical, Inc. (NASDAQ:AEMD) during the 3rd quarter, according to its most recent filing with the SEC. The fund acquired 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned approximately 36.57% of Aethlon Medical as of its most recent SEC filing. Institutional investors own 1.99% of the company’s stock.

About Aethlon Medical

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.